{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_names_name in Any Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
Green Body by Evercarepharm Co., Ltd
(2012)
Source URL:
First approved in 2012
Source:
Green Body by Evercarepharm Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2010)
Source URL:
First approved in 2009
Source:
M021
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA103189
(2009)
Source URL:
First approved in 2009
Source:
BLA103189
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2000
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
ANDA074164
(1997)
Source URL:
First approved in 1997
Source:
ANDA074164
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2022)
Source URL:
First approved in 1968
Source:
ANDA212706
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Investigational
Source:
NCT01732211: Phase 2 Interventional Terminated Pulmonary Sarcoidosis
(2013)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT04708470: Phase 1/Phase 2 Interventional Recruiting Oropharyngeal Cancer
(2021)
Source URL:
Class:
CONCEPT